Neurophos is a private company building in semiconductors / ai hardware. Its shares do not trade on a public exchange.
Neurophos has no published valuation.
Neurophos is an Austin-based semiconductor company developing high-performance, energy-efficient photonic AI inference chips, building toward its Tulkas T100 optical processing unit, which ships in 2028. It was co-founded by Duke-trained scientists Patrick Bowen and Andrew Traverso and spun out of the lab of Professor David Smith at Duke University, and it packages over one million micron-scale optical processing elements onto a single chip.
The OPU is designed as a drop-in replacement for GPUs in data centers, delivering up to 100 times the performance and energy efficiency of current leading chips. Neurophos's metamaterial optical modulators are a 10,000 times miniaturization over previous photonic elements, making large-scale, manufacturable photonic computing possible for the first time.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Neurophos.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Neurophos availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Neurophos included.
Lead investors for each round are in the funding timeline.
The closest semiconductors / ai hardware peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Neurophos is a private company; its shares do not trade on a public exchange.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
